Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.11 USD
Change Today -0.10 / -3.12%
Volume 1.3M
SGYP On Other Exchanges
Symbol
Exchange
NASDAQ GS
NASDAQ CM
As of 8:10 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

synergy pharmaceuticals inc (SGYP) Snapshot

Open
$3.19
Previous Close
$3.21
Day High
$3.22
Day Low
$3.05
52 Week High
03/21/14 - $6.29
52 Week Low
10/10/14 - $2.45
Market Cap
300.5M
Average Volume 10 Days
1.7M
EPS TTM
$-0.92
Shares Outstanding
96.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNERGY PHARMACEUTICALS INC (SGYP)

synergy pharmaceuticals inc (SGYP) Related Businessweek News

No Related Businessweek News Found

synergy pharmaceuticals inc (SGYP) Details

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders, as well as is in Phase IIb clinical trials for the treatment of constipation-predominant irritable bowel syndrome GI disorders. The company also develops SP-333, which is in Phase II clinical trials to treat GI inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.

25 Employees
Last Reported Date: 03/17/14

synergy pharmaceuticals inc (SGYP) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $680.0K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $279.9K
Chief Scientific Officer
Total Annual Compensation: $368.5K
Compensation as of Fiscal Year 2013.

synergy pharmaceuticals inc (SGYP) Key Developments

Synergy Pharmaceuticals, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 01:25 PM

Synergy Pharmaceuticals, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 01:25 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Gary S. Jacob, Chairman, Chief Executive Officer and President.

Synergy Pharmaceuticals Completes Patient Enrollment for the Second Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation

Synergy Pharmaceuticals Inc. announced that it has successfully completed patient enrollment in the second of two pivotal phase 3 trials evaluating the safety and efficacy of two plecanatide doses (3.0 and 6.0 mg) in patients with chronic idiopathic constipation (CIC). Synergy announced that it had completed patient enrollment in the first phase 3 CIC trial on January 8, 2015. Each of the two randomized, 12-week, double-blind, placebo-controlled phase 3 trials are evaluating plecanatide, once-daily oral tablets, in approximately 1350 adult patients with CIC. The primary endpoint is the proportion of patients who are Overall Responders during the 12-week treatment period. An Overall Responder is a patient who fulfills both ¥3 complete spontaneous bowel movements (CSBMs) per week plus an increase of ¥1 CSBM from baseline in the same week, for 9 out of the 12 weeks, including ¥3 of the last 4 weeks. Plecanatide has met this endpoint and demonstrated statistical significance at the 3.0 mg dose in a phase 2b CIC trial evaluating 951 patients with CIC. Synergy expects top-line data results from the first phase 3 CIC trial in second quarter of 2015 and top-line data results from the second phase 3 CIC trial in third quarter of 2015. The company plans to file its first NDA with plecanatide in the CIC indication in the fourth quarter of this year. Plecanatide 3.0 and 6.0 mg doses are also being evaluated in the ongoing phase 3 registration program for irritable bowel syndrome with constipation (IBS-C).

Synergy Pharmaceuticals, Inc. Completes Patient Enrollment for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation

Synergy Pharmaceuticals Inc. announced that it has successfully completed patient enrollment in the first of two pivotal phase 3 trials evaluating the safety and efficacy of two plecanatide doses (3.0 and 6.0 mg) in patients with chronic idiopathic constipation (CIC). The randomized, 12-week, double-blind, placebo-controlled pivotal phase 3 CIC trial is evaluating plecanatide 3.0 and 6.0 mg, once-daily oral tablets, in approximately 1,350 adult patients with CIC. The primary endpoint is the proportion of patients who are Overall Responders during the 12-week treatment period. An Overall Responder is a patient who fulfills both ¥3 complete spontaneous bowel movements (CSBMs) per week plus an increase of ¥1 CSBM from baseline in the same week, for 9 out of the 12 weeks. Plecanatide has met this endpoint and demonstrated statistical significance at the 3.0 mg dose in a phase 2b CIC trial evaluating 951 patients with CIC. Synergy expects top-line data results from the first phase 3 CIC trial in Second Quarter 2015. The company plans to file its first NDA with plecanatide in the CIC indication in the fourth quarter of this year. Plecanatide 3.0 and 6.0 mg doses are also being evaluated in the ongoing phase 3 registration program for irritable bowel syndrome with constipation (IBS-C).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SGYP:US $3.11 USD -0.10

SGYP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €14.60 EUR +0.09
Ironwood Pharmaceuticals Inc $15.81 USD +0.045
Sucampo Pharmaceuticals Inc $15.64 USD +0.49
View Industry Companies
 

Industry Analysis

SGYP

Industry Average

Valuation SGYP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 16.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNERGY PHARMACEUTICALS INC, please visit www.synergypharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.